

February 5, 2016

News Release

Company: Olympus Corporation
Representative Director, President: Hiroyuki Sasa
(Code: 7733, First Section, Tokyo Stock Exchange)
Contact: Tetsuo Hyakutake, General Manager, Public Relations and IR Office

Notice of Recognition of Additional Extraordinary Loss Relating to the Investigation by the U.S. Government Against Our Subsidiary Concerning the U.S. Anti-Kickback Statute and U.S. False Claims Act

Olympus Corporation hereby announces that it has recognized an extraordinary loss for the third quarter of the fiscal year ending on March 31, 2016.

1. Recognition of Extraordinary Loss

As mentioned in the May 8, 2015 release titled “Recognition of Extraordinary Loss Due to the Investigation by the U.S. Department of Justice Against Our Subsidiary and Notice of Difference Between Consolidated Earnings Forecast and Actual Results,” we recorded an approximately 53.9 billion yen extraordinary loss in our consolidated results for the fiscal year ending March 2015 in connection with investigation by the U.S. Department of Justice (the “DOJ”) against Olympus Corporation of the Americas, a U.S. subsidiary of ours, for conduct raising concerns under the U.S. Anti-Kickback Statute and U.S. False Claims Act in its medical business in the United States. OCA has been continuing discussions with the DOJ towards a resolution, but in view of the developments in such discussions at the present time, we have recorded approximately 15.6 billion yen as an additional extraordinary loss.

2. Future prospects

There is no change to the consolidated earnings forecast for the fiscal year ending March 2016 as a result of this matter.

End